• Phase

    Startup

  • Contact person

    Michael Rutzler, CEO

  • Email

    michael.rutzler@apoglyx.com 

  • Area

    Biotech

Apoglyx

Apoglyx AB is focused on innovative and novel medicines for acute systemic inflammatory diseases like acute pancreatitis, COVID-19 and sepsis, where an overreaction of the immune system harms the body’s own organs.

The company is based on the fundamental discovery of aquaporins by Nobel Laureate professor Peter Agre, Johns Hopkins University Medical School, and the extensive, collaborative scientific work with ApoGlyx founders Søren Nielsen, and Michael Rützler, at Århus University, Denmark and Per Kjellbom, Lund University, to establish that aquaporins are key pharmaceutical targets in life-threatening diseases.

News

© 2021 Copyright SmiLe Incubator